New drug combo aims to stop rare lymphoma from coming back after transplant
NCT ID NCT07276698
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of two drugs, selinexor and azacitidine, can help prevent NK/T-cell lymphoma from returning after a stem cell transplant. About 39 adults aged 18-70 who have already received a transplant will take these drugs as maintenance therapy. The goal is to see if this approach improves survival and reduces recurrence with manageable side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NK/T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for tough lymphoma: TR115 faces off against standard care
- New blood test could help monitor T-Cell lymphoma
- New vaccine aims to fight Hard-to-Treat EBV cancers
- New combo attack on rare blood cancer shows promise in early trial
- Triple-Drug attack aims to beat rare lymphoma
- New combo therapy aims to cut relapse in rare lymphoma